Viralytics: Cavatak Data Continue To Impress
Edison | Nov 21, 2016 08:11AM ET
Viralytics Ltd's (AX:VLA)Cavatak continues to impress, with a 100% disease control rate in 10 patients (seven objective responses) in combination with Keytruda in the CAPRA Phase Ib study. Furthermore, in the MITCI Phase Ib trial Cavatak, in combination with Yervoy, achieved a 50% response rate in the first 18 patients treated, which is an impressive response rate in a heavily pre-treated population. The encouraging results are a good sign for the ongoing trials of Cavatak and are likely to be of great interest to potential partners. We have increased our anticipated deal value assumptions for Viralytics following recent deals in oncolytic virotherapy, which lifts our valuation to A$385m or A$1.60/share.
Impressive preliminary data from MITCI and CAPRA
Updated results from the ongoing MITCI and CAPRA Phase Ib trials of Cavatak in combination with immune checkpoint inhibitors (ICIs) Yervoy and Keytruda, respectively, were presented at SITC in November 2016. All 10 patients showed a disease control rate in the CAPRA study evaluating intratumoral Cavatak in combination with Keytruda in advanced melanoma; seven of 10 patients (70%) showed an objective response rate and 30% had stable disease. In the MITCI trial, 9/18 (50%) patients with advanced melanoma had objective responses with Cavatak in combination with Yervoy. This compares favourably with reported response rates of 28% for Cavatak, 11% for Yervoy and 33% for Keytruda, as single agents.
To read the entire report Please click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.